Company Overview: Neumus

Industry News

9 May

Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Receives Second Patent Issued in the United States Related to Proprietary Delivery Mechanisms for Treatment of Glaucoma

COSTA MESA, CA–(Marketwired – May 9, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) announced that an additional United States patent has been granted covering the company’s proprietary prodrug of THC, THC-valine-hemisuccinate (THCVHS), as well as other amide-ester forms of cannabinoid-based molecules, for use in the treatment...

Read more

22 Mar

NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms

COSTA MESA, CA–(Marketwired – Mar 22, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) and the company’s discovery and research partner, the University of Mississippi (UM), today announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA...

Read more

20 Mar

Nemus Bioscience Signs Development Agreement with Nanomerics to Advance Ocular Formulation of NB1111 for the Treatment of Glaucoma Using Proprietary Molecular Envelope Technology (MET)

COSTA MESA, CA–(Marketwired – Mar 20, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) announced that the company has signed a development agreement with Nanomerics Ltd. of the United Kingdom, to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, which is the active...

Read more

13 Feb

Nemus Bioscience Reports Favorable Bio-distribution and Anti-Addictive Findings Versus Plant-Derived Cannabidiol (CBD) in Animal Model Studies of NB2111, an Analogue of Cannabidiol

COSTA MESA, CA / ACCESSWIRE / February 13, 2017 / NEMUS Bioscience, Inc. (NMUS) announced that the company and its research and development partner, the University of Mississippi School of Pharmacy (UM), have conducted in vitro and in vivo bio-distribution and anti-addictive studies of NB2111, a unique analogue of...

Read more

11 Jan

Nemus Bioscience Announces Licensing Agreement with the University of Mississippi (UM) for a Cannabinoid-Based Anti-infective Platform Directed Against Drug-Resistant Organisms

COSTA MESA, CA / ACCESSWIRE / January 11, 2017 / NEMUS Bioscience, Inc. (NMUS) announced that the company had signed a licensing agreement with the University of Mississippi (UM) for a platform of cannabinoid-based molecules (UM5070) for potential anti-infective use against bacteria, viruses, and fungi. The agreement culminates roughly...

Read more

10 Jan

NEMUS Bioscience Announces Closing of $1,200,000 Preferred Stock Financing

COSTA MESA, CA / ACCESSWIRE / January 10, 2017 / NEMUS Bioscience, Inc. (NMUS) today announced the closing of its Preferred Stock financing for gross proceeds of $1,200,000. Roth Capital Partners acted as the exclusive placement agent for the transaction. ABOUT NEMUS BIOSCIENCE, INC. The Company is a biopharmaceutical...

Read more

29 Dec

Nemus Bioscience Announces Preferred Stock Financing

COSTA MESA, CA / ACCESSWIRE / December 29, 2016 / NEMUS Bioscience, Inc. (NMUS) today announced that it entered into a Securities Purchase Agreement with certain purchasers for the sale of up to 1,500 shares of Series D Preferred Stock for gross proceeds of up to $1,500,000. Each share...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address